US Pharma MarketingThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
Source: BioPharma Dive